Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BB-2516: Began U.K. tests

British Biotech plc (BBIOY), Oxford, U.K.
Product: Batimastat matrix metalloproteinase inhibitor
Indication: Malignant

Read the full 137 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE